Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

Geode Capital Management LLC lifted its stake in PDS Biotechnology Co. (NASDAQ:PDSB) by 9.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 415,113 shares of the company’s stock after purchasing an additional 37,142 shares during the period. Geode Capital Management LLC owned about 1.13% of PDS Biotechnology worth $1,586,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Blair William & Co. IL boosted its position in PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after buying an additional 81,743 shares during the period. XTX Topco Ltd boosted its holdings in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the period. Cubist Systematic Strategies LLC bought a new position in PDS Biotechnology in the second quarter worth approximately $146,000. Squarepoint Ops LLC purchased a new position in PDS Biotechnology during the 2nd quarter worth $120,000. Finally, Vontobel Holding Ltd. increased its holdings in PDS Biotechnology by 233.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after purchasing an additional 28,000 shares during the period. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, December 18th. B. Riley dropped their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. Finally, StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Down 6.5 %

Shares of NASDAQ PDSB opened at $1.57 on Thursday. PDS Biotechnology Co. has a 1-year low of $1.53 and a 1-year high of $6.68. The business has a fifty day moving average price of $2.18 and a 200 day moving average price of $2.92. The stock has a market capitalization of $58.73 million, a P/E ratio of -1.35 and a beta of 1.90. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.